What is the recommended dose of glucagon (Glucagon) for treating hypoglycemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Glucagon Dosing for Hypoglycemia

For severe hypoglycemia, administer 1 mg glucagon for adults and children weighing >25 kg (or ≥6 years old), and 0.5 mg for children weighing ≤25 kg (or <6 years old), via subcutaneous, intramuscular, or intravenous routes. 1

Standard Dosing by Weight and Age

Adults and Larger Children

  • 1 mg (1 mL) is the recommended dose for patients weighing more than 25 kg or age 6 years and older 1
  • Can be administered subcutaneously, intramuscularly (upper arm, thigh, or buttocks), or intravenously 1
  • If no response after 15 minutes, an additional 1 mg dose may be given using a new kit while waiting for emergency assistance 1

Pediatric Patients (Smaller Children)

  • 0.5 mg (0.5 mL) is the recommended dose for children weighing less than 25 kg or younger than 6 years of age 1
  • Same routes of administration apply (subcutaneous, intramuscular, or intravenous) 1
  • If no response after 15 minutes, an additional 0.5 mg dose may be administered 1

Route Considerations and Expected Response

Route Selection

  • No clinically significant difference exists between subcutaneous and intramuscular administration in terms of efficacy for raising blood glucose 2
  • Intravenous administration produces higher initial plasma glucagon levels and a steeper rise in blood glucose during the first 5 minutes, but maximal glucose increase is similar across all routes 2
  • In practice, subcutaneous or intramuscular routes are preferred in out-of-hospital settings due to ease of administration 1

Timeline for Response

  • Blood glucose typically increases within 5-15 minutes after glucagon administration 3, 4, 5
  • Recovery of consciousness after intramuscular glucagon averages 6.5 minutes, compared to 4.0 minutes with intravenous dextrose 6
  • The slightly slower recovery with glucagon compared to IV dextrose is clinically acceptable given the ease of administration and lower risk of complications 6

Post-Administration Management

Immediate Follow-Up

  • Call for emergency assistance immediately after administering the dose 1
  • Monitor blood glucose every 15 minutes until levels exceed 70 mg/dL (3.9 mmol/L) 5
  • Once the patient responds and can swallow safely, give 15-20 g of oral carbohydrates to restore liver glycogen and prevent recurrence 5, 1
  • Follow with a meal or protein-containing snack 5

Common Side Effects

  • Nausea and vomiting are common, particularly with standard doses 4, 5
  • Lower doses (10 mcg/kg) result in smaller glycemic responses but less nausea, though this is primarily relevant for mini-dose glucagon protocols used for mild hypoglycemia 4

Alternative Formulations

Intranasal Glucagon

  • 3 mg intranasal dose is now available and preferred by the American Diabetes Association due to ease of administration 4
  • Shown to be noninferior to intramuscular glucagon, with >98% success rate in treating hypoglycemic events 7
  • Does not require reconstitution and can be administered in less than one minute 7
  • Particularly useful for caregivers uncomfortable with injections 7

Critical Clinical Pearls

Administration Technique

  • Traditional glucagon kits require reconstitution: inject all liquid from the prefilled syringe into the powder vial, shake gently until completely dissolved, then withdraw and inject 1
  • The reconstituted solution should be clear and colorless; discard if cloudy or contains particles 1
  • Use immediately after reconstitution and discard any unused portion 1

Safety Considerations

  • Never attempt oral glucose in a seizing or unconscious patient due to aspiration risk 5
  • Do not delay glucagon administration to obtain intravenous access in prehospital or home settings 5
  • Glucagon should be prescribed for all patients at increased risk for clinically significant hypoglycemia 3, 4
  • Train caregivers, family members, and close contacts on glucagon administration 3, 4

Storage and Replacement

  • Replace glucagon products when they reach expiration date 3, 4
  • Store according to specific product instructions 3

References

Guideline

Glucagon Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Glucagon Administration for Severe Hypoglycemia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Hypoglycemic Seizures

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.